Tag: Wuhan Zhong Yuan Rui De Biologics
CSL to buy majority stake in a leading Chinese plasma fractionator
Australian biotech firm CSL has agreed to acquire an 80% stake in China’s plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biologics (Ruide) in...
Featured Article
Xometry CEO Sanjeev Singh Sahni on how AI and digital networks are reshaping manufacturing supply chains
Australian manufacturers have long competed against distance. In an exclusive interview with Australian Manufacturing, Xometry CEO Sanjeev Singh Sahni discusses how AI can help manufacturers access more production capacity and simplify traditionally email-driven supply chains.
